Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Benzylpenicillin

Clinical medicine profile

Benzylpenicillin

Beta-lactam antibiotic — penicillin

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL / PARENTERAL (agent-dependent)
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • History of serious immediate hypersensitivity (e.g. anaphylaxis, angioedema, urticaria) to any penicillin.
  • Caution with prior severe cephalosporin reaction (cross-reactivity risk).
  • Avoid in infectious mononucleosis if using aminopenicillins (rash risk).

Precautions

  • Sufficient therapy to eliminate streptococcal infections.
  • Serious and occasionally fatal immediate hypersensitivity reactions may occur.
  • False-positive urinary glucose (if tested for reducing substances).
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

For most infections, doses of 0.6 to 4.8 g of benzylpenicillin daily in 2 to 4 divided doses by intramuscular or slow intravenous injection or intravenous infusion may be adequate, but higher doses given intravenously, often by infusion, are more usual for severe infections. Mild to moderate susceptible infections [including throat infec- tions, otitis media, pneumonia, cellulitis, neonatal sepsis]. By intramuscular injection or by slow intravenous injection or infusion [intravenous route recommended in neonates and infants] Neonate under 7 days: 25 mg/kg every 12 hours; dose doubled in severe infection. Neonate 728 days: 25 mg/kg every 8 hours; dose doubled in severe infection Child 1 month18 years: 25 mg/kg every 6 hours; increased to 50 mg/kg every 46 hours [max. 2.4 g every 4 hours] in severe infection Endocarditis [combined with another antibacte- rial if necessary] By slow intravenous injection or infusion Child 1 month18 years: 25 mg/kg every 4 hours, increased if necessary to 50 mg/kg [max. 2.4 g] every 4 hours Meningitis, meningococcal disease By slow intravenous injection or infusion Neonate: 75 mg/kg every 8 hours Child 1 month18 years: 50 mg/kg every 46 hours [max. 2.4 g every 4 hours] Proven or suspected neonatal group B strepto- coccus infection By slow intravenous injection or infusion Neonate under 7 days: 50 mg/kg every 12 hours Neonate 728 days: 50 mg/kg every 8 hours

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Renal excretion dominant — reduce dose or extend interval in significant renal impairment; risk of accumulation and seizures at high levels.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Low intrinsic hepatotoxicity; cholestatic hepatitis rare (notably flucloxacillin/co-amoxiclav patterns for related agents).

03 Clinical use

Use, effects & interactions

Indications

  • Streptococcal (including pneumococcal), gonococcal, and meningococcal infections, anthrax, diphtheria, gas-gangrene, leptospirosis, lyme disease.
  • Clinical selection for Benzylpenicillin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Beta-lactam antibiotic — penicillin.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction
  • rarely CNS toxicity including convulsions (especially with high doses or in severe renal impairment), interstitial nephritis, haemolytic anaemia, leucopenia, thrombocytopenia and coagulation disorders
  • also reported diarrhoea (including antibiotic-associated colitis).
  • Narrow-spectrum penicillin
  • verify hypersensitivity history.
  • Serious immediate hypersensitivity reactions can occur even with previous tolerance.
  • Use only for proven or strongly suspected bacterial infection.
  • Adjust dosage/frequency in severe renal impairment and in neonates with incompletely developed renal function.
  • 1 mg of penicillin G = 1667 units
04 Pharmacology

Mechanism & disposition

Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal.

Bind PBPsBlock wall cross-linkingOsmotic lysisBactericidal
Read complete mechanism

Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal. Penicillins bind penicillin-binding proteins (PBPs) and inhibit the final transpeptidation step of peptidoglycan synthesis, weakening the bacterial cell wall. Osmotic lysis follows; activity is bactericidal against susceptible organisms in the growth phase. Spectrum and beta-lactamase stability vary by agent (narrow natural penicillins vs aminopenicillins vs antipseudomonal/anti-staphylococcal agents).

Onset

Within 1 hour (oral); faster IV

Duration

4–8 hours typical (agent/formulation dependent)

Route

ORAL / PARENTERAL (agent-dependent)

Elimination

is predominantly renal (glomerular filtration and tubular secretion). Dose adjustment is often required in severe renal impairment. Probenecid reduces tubular secretion and prolongs levels.

Half-life

differ by agent and salt/ester. Most penicillins distribute widely into extracellular fluid; CSF penetration is poor unless meninges are inflamed.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Penicillins are generally considered compatible in pregnancy when clearly indicated (decades of clinical use). Prefer agents with the best safety record for the indication; confirm current SmPC.

Lactation

Usually compatible with breastfeeding; small amounts excreted in milk. Monitor infant for diarrhoea, thrush or rash.

06 Kenya market

Brands & loaded prices

FromKES 15
MedianKES 15
Listings5
BrandManufacturerPackObserved price
BENZYL BENZOATE Not recorded 100ML KES 34.40Daima Chemist price-list reference ↗ Source date not recorded · verify current price
CYDINE Not recorded 1 MEGA INJ VIAL 1*S KES 15.05Daima Chemist price-list reference ↗ Source date not recorded · verify current price
CYDINE INJECTION MEDCURE HEALTHCARE LTD Powder For Injection Unavailable
GLAPEN Benzylpenicillin for injection 1mega Powder For Injection Unavailable
KAREMEGA 1 INJECTION KAREMAX INDUSTRIAL LTD Powder For Solution For Injection Unavailable
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Beta-lactam antibiotic — penicillin)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.